Paclitaxel- and platinum-based chemotherapy
PreclinicalSmall molecule
Paclitaxel- and platinum-based chemotherapy is one of 18 small molecule programs targeting Esophageal Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Esophageal Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Taxol
TevaPhase 3
Taxotere
AAvyxa
Approved
Adrucil
EElorac, Inc.
Approved
Lenvima
EisaiPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Abraxane
Bristol-Myers SquibbPhase 2
Neoadjuvant Chemotherapy
JJapan Clinical Oncology Group
Phase 3
Paraplatin
AAvyxa
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHenan Cancer Hospital